ReviewCureus2026
Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyendocrine metabolic ovarian syndrome (PMOS), previously known by the name 'polycystic ovary syndrome (PCOS),' is a common and complex endocrine-metabolic disorder affecting approximately one in eight women. PMOS is increasingly regarded as a multisystem disorder rather than only a gynaecological condition. Exclusive of weight loss, metformin has been the mainstay pharmacological therapy in the treatment of PMOS; a new contender for the management of this condition is liraglutide. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RAs) and has gained increasing interest because it targets appetite regulation, body weight, and glycemic control as well as insulin sensitivity. There remains no comprehensive and up-to-date synthesis specifically comparing liraglutide versus metformin across clinically important outcomes in women with PMOS. This systematic review and meta-analysis aims to comprehensively evaluate these outcomes and provide evidence to guide individualized therapeutic decision-making. This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PRISMA). The research protocol was registered under the International Prospective Register of Systematic Reviews (PROSPERO), and the proposal is available under registration number CRD420261435182. No statistically significant difference in BMI between liraglutide and metformin (mean difference (MD)=0.25, 95% confidence interval (CI): -7.30-7.79, P=0.95, I²=82%, p=0.02). The pooled result of Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) favored metformin but showed no statistical difference between liraglutide and metformin (MD=0.94, 95% CI: -0.09-1.97, P=0.07, I²=0%, chi-square=0.14, p=0.71). Although the pooled effect favored metformin due to a higher frequency of the menstrual cycle, there was no significant difference between liraglutide and metformin (MD = -1.42, 95% CI: -4.57-1.73, P = 0.38, I² = 75%). A fixed-effect meta-analysis demonstrated no significant difference in fasting glucose levels between liraglutide and metformin (MD=-0.01 mmol/l, 95 % CI: - 0.82-0.80, P=0.98, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.